Argyrin B a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i

Allardyce, Duncan ORCID: https://orcid.org/0000-0001-7895-2640, Bell, Celia M. ORCID: https://orcid.org/0000-0002-3270-7081 and Loizidou, Erika ORCID: https://orcid.org/0000-0002-4834-6639 (2019) Argyrin B a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i. Chemical Biology and Drug Design, 94 (2) . pp. 1556-1567. ISSN 1747-0277 [Article] (doi:10.1111/cbdd.13539)

Preview

PDF - Final accepted version (with author's formatting) Download (291kB) | Preview

Abstract

Inhibitors of the proteasome have found broad therapeutic applications however, they show severe toxicity due to the abundance of proteasomes in healthy cells. In contrast, inhibitors of the immunoproteasome, which is upregulated during disease states, are less toxic and have increased therapeutic potential including against autoimmune disorders. In this project, we report argyrin B, a natural product cyclic peptide to be a reversible, non-competitive inhibitor of the immunoproteasome. Argyrin B showed selective inhibition of the β5i and β1i sites of the immunoproteasome over the β5c and β1c sites of the constitutive proteasome with nearly 20-fold selective inhibition of β1i over the homologous β1c. Molecular modelling attributes the β1i over β1c selectivity to the small hydrophobic S1 pocket of β1i and β5i over β5c to site-specific amino acid variations that enable additional bonding interactions and stabilization of the binding conformation. These findings facilitate the design of immunoproteasome selective and reversible inhibitors that may have a greater therapeutic potential and lower toxicity.

Actions (login required)

View Item

Statistics

DownloadsShow export options

Export as CSVXMLJSON

Activity Overview

6 month trend

275Downloads

6 month trend

347Hits

Additional statistics are available via IRStats2.